tiprankstipranks
Revance Therapeutics (RVNC)
NASDAQ:RVNC
US Market

Revance Therapeutics (RVNC) Income Statement

Compare
626 Followers

Revance Therapeutics Income Statement

Last quarter (Q3 2024), Revance Therapeutics's total revenue was $59.88M, an increase of 5.47% from the same quarter last year. In Q3, Revance Therapeutics's net income was $-35.12M. See Revance Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 234.04M$ 132.56M$ 77.80M$ 15.32M$ 413.00K
Gross Profit
$ 81.88M$ 80.90M$ 54.39M$ 10.56M$ -102.45M
Operating Expenses
$ 398.65M$ 353.07M$ 329.06M$ 283.72M$ 164.87M
Depreciation and Amortization
$ 13.69M$ 33.73M$ 19.85M$ 10.25M$ 2.91M
EBITDA
$ -290.64M$ -305.52M$ -255.18M$ -259.31M$ -156.52M
Operating Income
$ -316.78M$ -272.17M$ -274.68M$ -273.16M$ -164.46M
Other Income/Expenses
$ -6.91M$ -13.76M$ -6.63M$ -11.55M$ 5.03M
Pretax Income
$ -323.69M$ -355.72M$ -281.31M$ -284.71M$ -159.43M
Net Income
$ -323.99M$ -356.42M$ -286.82M$ -282.09M$ -156.22M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -3.83$ -4.90$ -4.25$ -4.86$ -3.59
Diluted EPS
$ -3.83$ -4.90$ -4.25$ -4.86$ -3.59
Weighted Average Shares Outstanding
84.60M 72.71M 67.51M 58.01M 43.46M
Weighted Average Shares Outstanding (Diluted)
84.60M 72.71M 67.51M 58.01M 43.46M
Currency in USD

Revance Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis